VIVES is a multi-sector fund that invests in projects with a positive societal impact
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
Axinesis is a spin-off of the Université catholique de Louvain (Belgium), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies...
A-Mansia is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (Belgium) and the University of Wageningen (the Netherlands)....
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Chris Buyse, Co founder and Managing Partner of Fund+ :
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the
European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of
This new fundraising secures the financing of its Phase IIB study for HepaStem® in its flagship indication, Acute on Chronic Liver Failure (ACLF), a severe liver disease affecting more than 50000